kras基因突变检测意义（Detection significance of KRAS gene mutation）.doc

kras基因突变检测意义（Detection significance of KRAS gene mutation） 1, detection significance Clinical targeted drugs Erbitux (Erbitux, cetuximab and panitumumab) (Panitumumab) applies only to the wild type K-RAS gene in patients with no mutations, mutation of K-RAS patients is invalid. The national comprehensive cancer network (NCCN) classified the K-RAS test as a guideline for clinical treatment of colon cancer. This kit is mainly used for high sensitivity, high throughput and low cost detection K-RAS mutation screening will assist clinicians, patients with effective love panitumumab, realize the individualized treatment of tumor patients, to reduce the risk of treatment and the burden of patients. 2, scope of application Colon cancer, gastric cancer, head and neck cancer, non-small cell lung cancer patients, for Erbitux or panitumumab targeted drug screening for the crowd. The kit is also suitable for early screening of cancers such as colon cancer, gastric cancer and pancreatic cancer. The kit is used to assist clinicians to screen patients with colorectal cancer who can benefit from anti EGFR therapy. It can provide scientific basis for the individual drug use, reduce the risk of treatment and reduce the medical burden of patients. Mutations in the KRAS gene are associated with primary resistance to targeted drugs such as tyrosine kinase inhibitors in patients with colorectal cancer. Wild type KRAS gene from patients with Erbitux (Erbitux, also known as cetuximab /Cetuximab) or vectibix (Vectibix, also called panitumumab /Panitumumab) treatment benefit, and the mutation of KRAS gene in colorectal cancer patients with poor therapeutic efficacy. The European Medicines Agency and the US FDA have clearly defined the need to test the KRAS gene prior to the use of targeted drugs for the treatment of metastatic colorectal cancer. Background introduction Monoclonal antibodies against epidermal growth factor receptor (EGFR) may compete with endogenous ligands to bind EGFR, block